BioVersys AG, a clinical-stage biopharmaceutical company developing novel antibacterial products for multidrug-resistant infections, announced that it will present new data on alpibectir together with its development partner GSK at The Union World Conference on Lung Health. The conference will take place from 17 to 20 November 2026 in Rio de Janeiro, Brazil. The presentations will include the latest Phase 2 results on alpibectir in combination with ethionamide (AlpE) in patients with newly diagnosed drug-sensitive pulmonary tuberculosis.
The Union World Conference on Lung Health brings together researchers, practitioners, advocates, policymakers, and communities from around the world to share knowledge and accelerate progress in lung health. The data to be presented at the conference will cover early bactericidal activity, safety, and pharmacokinetics of the AlpE combination, as well as its potential to potentiate ethionamide and overcome resistance in clinical isolates of Mycobacterium tuberculosis. The results stem from the ENABLE trial and the UNITE4TB platform, among other studies.
The news matters because tuberculosis remains a major global health threat, and drug-resistant strains complicate treatment. Alpibectir, a small molecule derived from BioVersys’ TRIC platform, acts through a novel mechanism to boost the activity of ethionamide, an anti-TB drug. By lowering the effective human dose of ethionamide, the combination may minimize dose-dependent side effects and help overcome resistance. This could lead to a more tolerable and effective treatment option for pulmonary TB and TB meningitis, addressing a high unmet medical need.
The development of AlpE has already received regulatory recognition. In 2023, the U.S. Food and Drug Administration granted orphan-drug designation for the treatment of tuberculosis, providing certain incentives including seven years of U.S. market exclusivity. In 2025, the European Medicines Agency granted Orphan Designation, offering incentives including 10-year EU market exclusivity. These designations underscore the potential of the combination to fill a critical gap in TB therapy.
For investors and industry observers, the upcoming presentations at the Union Conference represent a key milestone for BioVersys, a company listed on the SIX Swiss Exchange. The data could influence future development decisions and partnership opportunities. The company’s most advanced programs include BV100 for Acinetobacter baumannii infections, currently in Phase 3, and alpibectir for tuberculosis in Phase 2 with GSK and a consortium including the University of Lille. The full release is available via www.newmediawire.com, and more information about BioVersys can be found at www.bioversys.com.
The Union World Conference on Lung Health provides a global stage for these findings, which could shape the future of TB treatment and offer hope to patients worldwide. As drug resistance continues to challenge global health, innovative approaches like AlpE are closely watched by the medical community and the pharmaceutical industry.
